Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$12.02

-0.43 (-3.45%)

16:09
11/06/18
11/06
16:09
11/06/18
16:09

Five Prime reports Q3 EPS ($1.37), consensus ($1.15)

Reports Q3 revenue $5.8M, consensus $7.4M. Cash, cash equivalents and marketable securities totaled $321.6M as of September 30, 2018, compared to $292.7M as of December 31, 2017. The increase in cash, cash equivalents and marketable securities was primarily attributable to $107.6 million in net proceeds from the January 2018 public offering of common stock and $34.5 million in milestone and upfront payments Five Prime received from collaboration partners, net of cash used by Five Prime in operations to advance its clinical stage programs as well as preclinical research and development.

  • 06

    Nov

  • 07

    Nov

  • 27

    Nov

FPRX Five Prime
$12.02

-0.43 (-3.45%)

06/15/18
JPMS
06/15/18
INITIATION
Target $19
JPMS
Neutral
Five Prime initiated with a Neutral at JPMorgan
JPMorgan analyst Eric Joseph started Five Prime Therapeutics with a Neutral rating and $19 price target. The analyst has some caution into the pancreatic data and expects shares to be range-bound in the near-term.
06/28/18
RAJA
06/28/18
INITIATION
RAJA
Market Perform
Five Prime initiated with a Market Perform at Raymond James
08/09/18
WELS
08/09/18
NO CHANGE
Target $35
WELS
Outperform
Five Prime price target lowered to $35 from $58 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Five Prime to $35 from $58 following review of Q2 operating results and on disappointing update on Cabira in PVNS. The analyst reiterates an Outperform rating on the shares.
09/13/18
LEER
09/13/18
INITIATION
Target $24
LEER
Outperform
Five Prime resumed with an Outperform at Leerink
Leerink analyst Jonathan Chang resumed coverage of Five Prime with an Outperforn rating and $24 price target. While investors are cautious on cabiralizumab following updates at the Society for Immunotherapy of Cancer 2017 with limited visibility into future clinical updates and next development steps, MEDACorp KOLs he has spoken to remain positive on the approach. Additionally, Chang sees multiple sources of upside from his current valuation including opportunities for cabiralizumab beyond pancreatic cancer as well as Five Prime's advancing early stage pipeline including FPA150, FPT155, and BMS-986258.

TODAY'S FREE FLY STORIES

IRWD

Ironwood

$11.96

0.32 (2.75%)

06:01
11/19/18
11/19
06:01
11/19/18
06:01
Recommendations
Ironwood analyst commentary  »

Ironwood price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:00
11/19/18
11/19
06:00
11/19/18
06:00
General news
FX Action: USD-JPY has retained a heavy tone »

FX Action: USD-JPY has…

YETI

Yeti

$16.99

0.1 (0.59%)

05:59
11/19/18
11/19
05:59
11/19/18
05:59
Initiation
Yeti initiated  »

Yeti initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RHHBY

Roche

$0.00

(0.00%)

05:57
11/19/18
11/19
05:57
11/19/18
05:57
Downgrade
Roche rating change  »

Roche downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 24

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

05:56
11/19/18
11/19
05:56
11/19/18
05:56
Upgrade
Novartis rating change  »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

TI

Telecom Italia

$6.02

0.12 (2.03%)

05:53
11/19/18
11/19
05:53
11/19/18
05:53
Hot Stocks
Telecom Italia appoints Luigi Gubitosi as CEO »

On Sunday, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNE

StoneCo

$25.31

0.69 (2.80%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Initiation
StoneCo initiated  »

StoneCo initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Downgrade
AstraZeneca rating change  »

AstraZeneca downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

JPDYY

Japan Display

$0.00

(0.00%)

05:49
11/19/18
11/19
05:49
11/19/18
05:49
Downgrade
Japan Display rating change  »

Japan Display downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$25.17

0.44 (1.78%)

05:46
11/19/18
11/19
05:46
11/19/18
05:46
Initiation
Retrophin initiated  »

Retrophin initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

YETI

Yeti

$16.99

0.1 (0.59%)

05:43
11/19/18
11/19
05:43
11/19/18
05:43
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

EOLS

Evolus

$14.75

0.06 (0.41%)

05:40
11/19/18
11/19
05:40
11/19/18
05:40
Hot Stocks
Evolus announces conditional acceptance from FDA for Jeuveau brand name »

Evolus announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

MNK

Mallinckrodt

$30.85

-0.58 (-1.85%)

05:39
11/19/18
11/19
05:39
11/19/18
05:39
Upgrade
Mallinckrodt rating change  »

Mallinckrodt upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

CPAC

Cementos Pacasmayo

$9.98

(0.00%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Cementos Pacasmayo rating change  »

Cementos Pacasmayo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Viking Therapeutics rating change  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$23.04

-1.18 (-4.87%)

05:37
11/19/18
11/19
05:37
11/19/18
05:37
Earnings
Breaking Earnings news story on JD.com »

JD.com sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

05:36
11/19/18
11/19
05:36
11/19/18
05:36
Downgrade
Madrigal Pharmaceuticals rating change  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

JD

JD.com

$23.04

-1.18 (-4.87%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Earnings
JD.com reports Q3 EPS 15c, consensus 10c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMH

American Homes 4 Rent

$19.83

-0.04 (-0.20%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Downgrade
American Homes 4 Rent rating change  »

American Homes 4 Rent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BB

BlackBerry

$8.97

0.12 (1.36%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMAX

RE/MAX Holdings

$30.26

-0.23 (-0.75%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RE/MAX Holdings rating change  »

RE/MAX Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

RNG

RingCentral

$76.41

-0.54 (-0.70%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RingCentral rating change  »

RingCentral upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Upgrade
TD Ameritrade rating change  »

TD Ameritrade upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$46.97

-0.35 (-0.74%)

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Downgrade
Charles Schwab rating change  »

Charles Schwab downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

05:32
11/19/18
11/19
05:32
11/19/18
05:32
Hot Stocks
Nissan finds 'significant acts of misconduct' by Representative Director »

Nissan said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.